Literature DB >> 10422632

Use of cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: report of two cases.

I Pérez-Sánchez1, J Anguita, T Pintado.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is an unusual complication of systemic lupus erythematosus (SLE). There are no randomized, prospective studies of its treatment. The association of plasma infusions and (or) plasmapheresis with steroids improves survival when compared with steroid treatment alone, but these patients still have a higher mortality than those with "classic" TTP. The role of immunosuppressive drugs in the management of this disorder remains uncertain. We report two cases of TTP in SLE which presumably benefited from the addition of cyclophosphamide to the treatment with plasmapheresis and steroids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10422632     DOI: 10.1007/s002770050516

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  Intravenous cyclophosphamide therapy in a case with refractory thrombotic microangiopathic hemolytic anemia and SLE.

Authors:  Jun Akaogi; Noriko Akasaka; Hidehiro Yamada; Nobuaki Hama; Minoru Satoh; Cody Nichols; Shoichi Ozaki
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

Review 2.  Clinical assessment and management of cytopenias in lupus patients.

Authors:  Alana B Levine; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.